UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000015101
Receipt number R000017574
Scientific Title A phase 1 trial of hepatic arterial infusion chemotherapy with high dose cisplatin and 5-fluorouracil for unresectable advanced and recurrent hepatocellular carcinoma
Date of disclosure of the study information 2014/09/10
Last modified on 2019/03/15 12:05:25

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A phase 1 trial of hepatic arterial infusion chemotherapy with high dose cisplatin and 5-fluorouracil for unresectable advanced and recurrent hepatocellular carcinoma

Acronym

A phase 1 trial of HAIC with high dose CDDP + 5-FU for advanced HCC

Scientific Title

A phase 1 trial of hepatic arterial infusion chemotherapy with high dose cisplatin and 5-fluorouracil for unresectable advanced and recurrent hepatocellular carcinoma

Scientific Title:Acronym

A phase 1 trial of HAIC with high dose CDDP + 5-FU for advanced HCC

Region

Japan


Condition

Condition

hepatocelllar carcinoma

Classification by specialty

Hepato-biliary-pancreatic medicine Hepato-biliary-pancreatic surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

Safety

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2


Developmental phase

Phase I


Assessment

Primary outcomes

Incidence of dose limiting toxicity

Key secondary outcomes

Adverse effect, response rate, progression free survival, safety


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Historical

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Hepatic arterial infusion chemotherapy with high dose CDDP and 5-FU

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) Histology/cytology-or clinically (by imaging or tumor marker) proven advanced hepatocellular carcinoma
2) ECOG PS of 0 or1
4) Child-Pugh A or B
5) The function of the major organ is kept as satisfied by the following requirement, a) Neutrophil >= 1,500/microL, b) Platelets >=50,000/microL, c) Hemoglobin >= 8.5g/dL
d) PT% >=40%, e) AST or ALT <= 5 *Upper limit of Normal(ULN), f) Cr <= 1.5 *ULN
6) written informed consent

Key exclusion criteria

(1) Active second primary malignancies.
(2) Within 3 years after radical treatment of another cancer
(3) With extrahepatic metastasis.
(4) Patients with ascites possessed clinical meaning.
(5) Hepatic Encephalopathy
(6) Critical renal failure or hemodialysis
(7) Contraindication of CDDP and 5-FU
(8) Any patients are pregnant/ nursing
(9) After administration of TS-1
(10) Auditory disorder
(11) Patients with serious infection
(12) Gastrointestinal ulcer or bleeding
(13) Uncontrolled DM
(14) Those judged to be not suitable by the attending physician

Target sample size

18


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Osamu Itano

Organization

Keio University, School of medicine

Division name

Department of Surgery

Zip code


Address

35, Shinanomachi, Shinjuku-ku, Tokyo

TEL

03-3353-1211

Email

contact@keio-hpbts.jp


Public contact

Name of contact person

1st name
Middle name
Last name Osamu Itano

Organization

Keio University, School of medicine

Division name

Department of Surgery

Zip code


Address

35, Shinanomachi, Shinjuku-ku, Tokyo

TEL

03-3353-1211

Homepage URL


Email

contact@keio-hpbts.jp


Sponsor or person

Institute

Keio University, School of medicine, Department of Surgery

Institute

Department

Personal name



Funding Source

Organization

Keio University, School of medicine, Department of Surgery

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2014 Year 09 Month 10 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2013 Year 05 Month 30 Day

Date of IRB

2013 Year 08 Month 31 Day

Anticipated trial start date

2013 Year 09 Month 01 Day

Last follow-up date

2019 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2014 Year 09 Month 10 Day

Last modified on

2019 Year 03 Month 15 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000017574


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name